APA (7th ed.) Citation

Su, Y., Li, J., Wang, C., Zhang, X., Hou, S., Guo, H., . . . Wang, J. (2023). Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis. Advances in therapy, 40(3), 1005-1018. https://doi.org/10.1007/s12325-022-02396-8

Chicago Style (17th ed.) Citation

Su, Yin, Jing Li, Chenguang Wang, Xunmin Zhang, Sheng Hou, Huaizu Guo, Chenhui Deng, Lun Ou, and Jinwei Wang. "Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis." Advances in Therapy 40, no. 3 (2023): 1005-1018. https://doi.org/10.1007/s12325-022-02396-8.

MLA (9th ed.) Citation

Su, Yin, et al. "Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis." Advances in Therapy, vol. 40, no. 3, 2023, pp. 1005-1018, https://doi.org/10.1007/s12325-022-02396-8.